BioCentury | Feb 29, 2020
Translation in Brief

Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation

Genentech identifies blood as source of antitumor T cells   In a Nature article , a Genentech Inc. team reported that non-exhausted T cell clones in the blood could act as a source of antitumor T...
BC Week In Review | Nov 23, 2015
Clinical News

MVA-BN Brachyury: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 38 patients with advanced metastatic solid cancers or chordoma showed that 1, 2 and 4 injections of once-monthly 2x10 8 plaque-forming units (PFUs) subcutaneous MVA-BN Brachyury for...
BC Week In Review | Aug 4, 2014
Clinical News

MVA-BN Brachyury: Phase I started

Bavarian Nordic began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1, 2 or 4 injections of 2x10 8 infectious units of subcutaneous MVA-BN Brachyury once monthly for 3 months in up to 28...
Items per page:
1 - 3 of 3